Acadia Pharmaceuticals announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID ‘740 composition of matter patent. The court ruled in favor of Acadia on all grounds. The ruling came in Acadia’s litigation against MSN Laboratories Pvt. Ltd., MSN Pharmaceuticals, Inc. and other ANDA filers and concludes this litigation in the District Court. The ‘740 composition of matter patent protects NUPLAZID into 2030. Acadia markets two forms of NUPLAZID, a 34mg capsule and a 10mg tablet. In addition to the ‘740 patent, Acadia has an issued method of use patent that protects the 10mg tablet to 2037 and multiple issued formulation patents that protect the 34mg capsule into 2038.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia Pharmaceuticals initiated with bullish view at Deutsche Bank, here’s why
- Acadia Pharmaceuticals initiates COMPASS PWS study
- Acadia Pharmaceuticals initiates ACP-204 study
- Acadia Pharmaceuticals head of R&D, Doug Williamson, M.D., to leave
- Acadia Pharmaceuticals price target raised to $40 from $38 at Canaccord